myelodysplastic/myeloproliferative neoplasm
myelodysplastic/myeloproliferative neoplasm
Explore linked clinical trials. Standard reference: MONDO:000631128 results · Page 1 of 2
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Randomized Study of ASTX727 With or Without Iadademstat in Advanced Myeloproliferative Neoplasms (MPNs) | Hemic and Lymphatic Diseases, Myeloproliferative Disorders, Neoplasms by Site, acquired polycythemia vera, blood coagulation disease, blood platelet disease, bone marrow disorder, bone marrow neoplasm, essential thrombocythemia, hematologic disorder, hematopoietic and lymphoid system neoplasm, hemorrhagic disease, myelodysplastic/myeloproliferative disease, myelodysplastic/myeloproliferative neoplasm, neoplasm, primary myelofibrosis, thrombocytosis disease | Recruiting | Phase 2 | 2026-09-30 | NCT06661915 | |
| CMV-MVA Triplex Vaccination of Stem Cell Donors in Preventing CMV Viremia in Participants With Allogeneic Transplant | B-cell chronic lymphocytic leukemia, Chronic Disease, Disease Attributes, Hemic and Lymphatic Diseases, Hodgkins lymphoma, Leukemia, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Chronic-Phase, Myeloproliferative Disorders, Neoplasms by Histologic Type, Neoplasms by Site, Pathologic Processes, Pathological Conditions, Signs and Symptoms, bone marrow disorder, hematologic disorder, hematopoietic and lymphoid cell neoplasm, hematopoietic and lymphoid system neoplasm, immune system disorder, immunoproliferative disorder, leukemia, leukemia, myeloid, accelerated-phase, lymphatic system disorder, lymphoid leukemia, lymphoma, lymphoproliferative syndrome, myelodysplastic syndrome, myelodysplastic/myeloproliferative disease, myelodysplastic/myeloproliferative neoplasm, myeloid leukemia, neoplasm, non-Hodgkin lymphoma, primary myelofibrosis | Active, not recruiting | Phase 1 | 2026-09-28 | NCT03560752 | |
| Edetate Calcium Disodium or Succimer in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Undergoing Chemotherapy | Carcinogenesis, Cell Transformation, Neoplastic, Chronic Disease, Disease Attributes, Hemic and Lymphatic Diseases, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Myeloproliferative Disorders, Neoplasms by Histologic Type, Neoplastic Processes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, acute myeloid leukemia, blast phase chronic myelogenous leukemia, BCR-ABL1 positive, bone marrow disorder, chronic myeloid leukemia, hematologic disorder, leukemia, myelodysplastic syndrome, myelodysplastic/myeloproliferative disease, myelodysplastic/myeloproliferative neoplasm, myeloid leukemia, myeloproliferative neoplasm, neoplasm, therapy related acute myeloid leukemia and myelodysplastic syndrome | Recruiting | Phase 1 | 2026-09-18 | NCT03630991 | |
| Decitabine With Ruxolitinib, Fedratinib or Pacritinib for the Treatment of Accelerated/Blast Phase Myeloproliferative Neoplasms | Hemic and Lymphatic Diseases, Myeloproliferative Disorders, Neoplasms by Histologic Type, Neoplasms by Site, acquired polycythemia vera, acute monocytic leukemia, acute myeloid leukemia, blood coagulation disease, blood platelet disease, bone marrow disorder, bone marrow neoplasm, essential thrombocythemia, hematologic disorder, hematopoietic and lymphoid system neoplasm, hemorrhagic disease, leukemia, myelodysplastic syndrome, myelodysplastic/myeloproliferative disease, myelodysplastic/myeloproliferative neoplasm, myeloid leukemia, myeloproliferative neoplasm, neoplasm, primary myelofibrosis, thrombocytosis disease | Recruiting | Phase 2 | 2026-09-17 | NCT04282187 | |
| A Study of BGB-11417 in Participants With Myeloid Malignancies | Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, acute myeloid leukemia, bone marrow disorder, hematologic disorder, leukemia, myelodysplastic syndrome, myelodysplastic/myeloproliferative disease, myelodysplastic/myeloproliferative neoplasm, myeloid leukemia, neoplasm | Recruiting | Phase 1 / Phase 2 | 2026-09-14 | NCT04771130 | |
| A Telehealth Advance Care Planning Intervention | Hemic and Lymphatic Diseases, Myeloproliferative Disorders, Neoplasms by Histologic Type, acute myeloid leukemia, bone marrow disorder, hematologic disorder, leukemia, myelodysplastic syndrome, myelodysplastic/myeloproliferative disease, myelodysplastic/myeloproliferative neoplasm, myeloid leukemia, myeloid neoplasm, neoplasm, primary myelofibrosis | Recruiting | Not applicable | 2026-09-11 | NCT05875805 | |
| Axatilimab With or Without Azacitidine for the Treatment of Patients With Advanced Phase Myeloproliferative Neoplasms, Myeloproliferative Neoplasm/Myelodysplastic Syndrome Overlap or High Risk Chronic Myelomonocytic Leukemia | Chronic Disease, Disease Attributes, Hemic and Lymphatic Diseases, Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative, Myeloproliferative Disorders, Neoplasms by Histologic Type, Pathologic Processes, Pathological Conditions, Signs and Symptoms, bone marrow disorder, chronic myelomonocytic leukemia, hematologic disorder, leukemia, myelodysplastic/myeloproliferative disease, myelodysplastic/myeloproliferative neoplasm, myeloid leukemia, neoplasm | Recruiting | Phase 1 / Phase 2 | 2026-08-27 | NCT06523556 | |
| GvHD Prophylaxis in Unrelated Donor HCT: Randomized Trial Comparing PTCY Versus ATG | acute myeloid leukemia, chronic myelomonocytic leukemia, graft versus host disease, immune system disorder, myelodysplastic syndrome, myelodysplastic/myeloproliferative neoplasm | Active, not recruiting | Phase 3 | 2026-08-27 | NCT05153226 | |
| Ruxolitinib Before, During and After Hematopoietic Cell Transplant in Older Patients With Myelofibrosis and Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap Syndromes | Hemic and Lymphatic Diseases, Myeloproliferative Disorders, bone marrow disorder, hematologic disorder, myelodysplastic/myeloproliferative disease, myelodysplastic/myeloproliferative neoplasm, primary myelofibrosis | Recruiting | Phase 2 | 2026-08-19 | NCT07228624 | |
| Venetoclax in Combination With ASTX727 for the Treatment of Chronic Myelomonocytic Leukemia and Other Myelodysplastic Syndrome/Myeloproliferative Neoplasm | Chronic Disease, Disease Attributes, Hemic and Lymphatic Diseases, Myeloproliferative Disorders, Neoplasms by Histologic Type, Pathologic Processes, Pathological Conditions, Signs and Symptoms, anemia, bone marrow disorder, chronic myelomonocytic leukemia, hematologic disorder, leukemia, myelodysplastic syndrome, myelodysplastic syndrome with excess blasts, myelodysplastic syndrome with single lineage dysplasia, myelodysplastic/myeloproliferative disease, myelodysplastic/myeloproliferative neoplasm, myeloid leukemia, myeloproliferative neoplasm, neoplasm | Active, not recruiting | Phase 2 | 2026-08-19 | NCT05600894 | |
| 3'-Deoxy-3'-[18F] Fluorothymidine PET Imaging in Patients With Cancer | B-cell chronic lymphocytic leukemia, B-cell neoplasm, Blood Protein Disorders, Burkitt lymphoma, Carcinogenesis, Cell Transformation, Neoplastic, Chronic Disease, Congenital Abnormalities, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, DNA Virus Infections, Disease Attributes, Epstein-Barr virus infection, Hemic and Lymphatic Diseases, Herpesviridae infectious disease, Hodgkins lymphoma, Immunoglobulin Light-chain Amyloidosis, Infections, Leukemia, B-Cell, Leukemia, Large Granular Lymphocytic, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative, Leukemia, Myeloid, Chronic-Phase, Lymphadenopathy, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Extranodal NK-T-Cell, Mast Cell Activation Disorders, Mastocytosis, Systemic, Myeloproliferative Disorders, Neoplasms by Histologic Type, Neoplasms by Site, Neoplastic Processes, Nutritional and Metabolic Diseases, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma, Sezary syndrome, T-cell leukemia, T-cell non-Hodgkin lymphoma, Tumor Virus Infections, Waldenstrom macroglobulinemia, acquired polycythemia vera, acute biphenotypic leukemia, acute myeloid leukemia, amyloidosis, anaplastic large cell lymphoma, angioimmunoblastic T-cell lymphoma, blast phase chronic myelogenous leukemia, BCR-ABL1 positive, blood coagulation disease, blood platelet disease, bone marrow disorder, bone marrow neoplasm, cardiovascular disorder, central nervous system cancer, chronic eosinophilic leukemia, chronic myelomonocytic leukemia, chronic neutrophilic leukemia, diffuse large B-cell lymphoma, essential thrombocythemia, follicular lymphoma, hairy cell leukemia, hematologic disorder, hematopoietic and lymphoid system neoplasm, hemorrhagic disease, immune system disorder, immunoproliferative disorder, intraocular lymphoma, large-cell immunoblastic lymphoma, leukemia, leukemia, myeloid, accelerated-phase, lymphatic system disorder, lymphoid leukemia, lymphoma, lymphoproliferative syndrome, mantle cell lymphoma, mast cell leukemia, mastocytosis, metabolic disease, monoclonal gammopathy, mycosis fungoides, myelodysplastic syndrome, myelodysplastic/myeloproliferative disease, myelodysplastic/myeloproliferative neoplasm, myeloid leukemia, neoplasm, nervous system disorder, ocular cancer, plasma cell neoplasm, primary cutaneous T-cell non-Hodgkin lymphoma, primary myelofibrosis, prolymphocytic leukemia, proteostasis deficiencies, thrombocytosis disease, vascular disorder, vascular hemostatic disease, viral infectious disease | Active, not recruiting | Not stated | 2026-08-10 | NCT00935090 | |
| Busulfan, Fludarabine Phosphate, and Post-Transplant Cyclophosphamide in Treating Patients With Blood Cancer Undergoing Donor Stem Cell Transplant | Blood Protein Disorders, Chronic Disease, Disease Attributes, Hemic and Lymphatic Diseases, Hodgkins lymphoma, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Myeloproliferative Disorders, Neoplasms by Histologic Type, Neoplasms by Site, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Precursor Cell Lymphoblastic Leukemia-Lymphoma, acute myeloid leukemia, bone marrow disorder, cardiovascular disorder, hematologic disorder, hematopoietic and lymphoid cell neoplasm, hematopoietic and lymphoid system neoplasm, hemorrhagic disease, immune system disorder, immunoproliferative disorder, leukemia, lymphatic system disorder, lymphoid leukemia, lymphoma, lymphoproliferative syndrome, monoclonal gammopathy, myelodysplastic syndrome, myelodysplastic/myeloproliferative disease, myelodysplastic/myeloproliferative neoplasm, myeloid leukemia, neoplasm, plasma cell neoplasm, vascular disorder, vascular hemostatic disease | Active, not recruiting | Phase 2 | 2026-08-06 | NCT02861417 | |
| Personalized NK Cell Therapy in CBT | Chronic Disease, Disease Attributes, Hemic and Lymphatic Diseases, Hodgkins lymphoma, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Chronic-Phase, Myeloproliferative Disorders, Neoplasms by Histologic Type, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Precursor Cell Lymphoblastic Leukemia-Lymphoma, acute biphenotypic leukemia, acute myeloid leukemia, anemia, bone marrow disorder, chronic myelomonocytic leukemia, hematologic disorder, immune system disorder, immunoproliferative disorder, leukemia, leukemia, myeloid, accelerated-phase, lymphatic system disorder, lymphoid leukemia, lymphoma, lymphoproliferative syndrome, myelodysplastic syndrome, myelodysplastic syndrome with excess blasts, myelodysplastic syndrome with single lineage dysplasia, myelodysplastic/myeloproliferative disease, myelodysplastic/myeloproliferative neoplasm, myeloid leukemia, neoplasm, therapy related acute myeloid leukemia and myelodysplastic syndrome | Recruiting | Phase 2 | 2026-07-30 | NCT02727803 | |
| Combination Chemotherapy (FLAG-Ida) With Pivekimab Sunirine (PVEK) for the Treatment of Newly Diagnosed Adverse Risk Acute Myeloid Leukemia and Other High-Grade Myeloid Neoplasms | Hemic and Lymphatic Diseases, Myeloproliferative Disorders, Neoplasms by Histologic Type, acute biphenotypic leukemia, acute myeloid leukemia, bone marrow disorder, hematologic disorder, immune system disorder, immunoproliferative disorder, leukemia, lymphatic system disorder, lymphoid leukemia, lymphoproliferative syndrome, mixed phenotype acute leukemia, myelodysplastic syndrome, myelodysplastic/myeloproliferative disease, myelodysplastic/myeloproliferative neoplasm, myeloid leukemia, myeloproliferative neoplasm, neoplasm | Active, not recruiting | Phase 1 | 2026-07-29 | NCT06034470 | |
| Phase I/II Study of Tagraxofusp in Combination With Decitabine for Patients With Myelomonocytic/Myeloproliferative Neoplasm and High Risk Myelodysplastic Syndromes | Chronic Disease, Disease Attributes, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, Pathologic Processes, Pathological Conditions, Signs and Symptoms, bone marrow disorder, chronic myelomonocytic leukemia, hematologic disorder, leukemia, myelodysplastic/myeloproliferative disease, myelodysplastic/myeloproliferative neoplasm, myeloid leukemia, neoplasm | Active, not recruiting | Phase 1 / Phase 2 | 2026-07-14 | NCT05038592 | |
| Registry of Older Patients With Cancer | B-cell chronic lymphocytic leukemia, B-cell neoplasm, Blood Protein Disorders, Burkitt lymphoma, Carcinogenesis, Cell Transformation, Neoplastic, Chronic Disease, Congenital Abnormalities, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, DNA Virus Infections, Disease Attributes, Epstein-Barr virus infection, Hemic and Lymphatic Diseases, Herpesviridae infectious disease, Hodgkins lymphoma, Immunoglobulin Light-chain Amyloidosis, Infections, Leukemia, B-Cell, Leukemia, Large Granular Lymphocytic, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative, Leukemia, Myeloid, Chronic-Phase, Lymphadenopathy, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Extranodal NK-T-Cell, Mast Cell Activation Disorders, Mastocytosis, Systemic, Myeloproliferative Disorders, Neoplasms by Histologic Type, Neoplasms by Site, Neoplastic Processes, Nutritional and Metabolic Diseases, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma, Sezary syndrome, T-cell leukemia, T-cell non-Hodgkin lymphoma, Tumor Virus Infections, Waldenstrom macroglobulinemia, acquired polycythemia vera, acute biphenotypic leukemia, acute myeloid leukemia, amyloidosis, anaplastic large cell lymphoma, angioimmunoblastic T-cell lymphoma, blast phase chronic myelogenous leukemia, BCR-ABL1 positive, blood coagulation disease, blood platelet disease, bone marrow disorder, bone marrow neoplasm, cardiovascular disorder, chronic eosinophilic leukemia, chronic myelomonocytic leukemia, chronic neutrophilic leukemia, diffuse large B-cell lymphoma, essential thrombocythemia, follicular lymphoma, hairy cell leukemia, hematologic disorder, hematopoietic and lymphoid system neoplasm, hemorrhagic disease, immune system disorder, immunoproliferative disorder, intraocular lymphoma, large-cell immunoblastic lymphoma, leukemia, leukemia, myeloid, accelerated-phase, lymphatic system disorder, lymphoid leukemia, lymphoma, lymphoproliferative syndrome, mantle cell lymphoma, mast cell leukemia, mastocytosis, metabolic disease, monoclonal gammopathy, mycosis fungoides, myelodysplastic syndrome, myelodysplastic/myeloproliferative disease, myelodysplastic/myeloproliferative neoplasm, myeloid leukemia, neoplasm, ocular cancer, plasma cell neoplasm, primary cutaneous T-cell non-Hodgkin lymphoma, primary myelofibrosis, prolymphocytic leukemia, proteostasis deficiencies, thrombocytosis disease, vascular disorder, vascular hemostatic disease, viral infectious disease | Recruiting | Not stated | 2026-06-29 | NCT01137825 | |
| Topotecan Hydrochloride and Carboplatin With or Without Veliparib in Treating Advanced Myeloproliferative Disorders and Acute Myeloid Leukemia or Chronic Myelomonocytic Leukemia | Chronic Disease, Disease Attributes, Hemic and Lymphatic Diseases, Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative, Myeloproliferative Disorders, Neoplasms by Histologic Type, Neoplasms by Site, Pathologic Processes, Pathological Conditions, Signs and Symptoms, acquired polycythemia vera, acute myeloid leukemia, blood coagulation disease, blood platelet disease, bone marrow disorder, bone marrow neoplasm, chronic myelomonocytic leukemia, essential thrombocythemia, hematologic disorder, hematopoietic and lymphoid system neoplasm, hemorrhagic disease, leukemia, myelodysplastic/myeloproliferative disease, myelodysplastic/myeloproliferative neoplasm, myeloid leukemia, neoplasm, primary myelofibrosis, thrombocytosis disease | Active, not recruiting | Phase 2 | 2026-06-23 | NCT03289910 | |
| Hyperbaric Oxygen Therapy and Allogeneic Peripheral Blood Stem Cell (PBSC) Transplant | Chronic Disease, Disease Attributes, Hemic and Lymphatic Diseases, Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative, Myeloproliferative Disorders, Neoplasms by Histologic Type, Pathologic Processes, Pathological Conditions, Signs and Symptoms, acute myeloid leukemia, bone marrow disorder, chronic myelomonocytic leukemia, hematologic disorder, leukemia, myelodysplastic syndrome, myelodysplastic/myeloproliferative disease, myelodysplastic/myeloproliferative neoplasm, myeloid leukemia, neoplasm, primary myelofibrosis | Recruiting | Early phase 1 | 2026-06-03 | NCT03964506 | |
| Phase Ib Study of CD33 FPBMC in Patients With MRD+ AML or MDS | Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, acute myeloid leukemia, bone marrow disorder, hematologic disorder, leukemia, myelodysplastic syndrome, myelodysplastic/myeloproliferative disease, myelodysplastic/myeloproliferative neoplasm, myeloid leukemia, neoplasm | Recruiting | Phase 1 | 2026-05-11 | NCT07270978 | |
| Ropeginterferon Alfa-2b for the Treatment of Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap Syndromes and Chronic Myelomonocytic Leukemia | Chronic Disease, Disease Attributes, Hemic and Lymphatic Diseases, Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative, Myeloproliferative Disorders, Neoplasms by Histologic Type, Pathologic Processes, Pathological Conditions, Signs and Symptoms, blood platelet disease, bone marrow disorder, chronic myelomonocytic leukemia, hematologic disorder, leukemia, myelodysplastic/myeloproliferative disease, myelodysplastic/myeloproliferative neoplasm, myeloid leukemia, neoplasm, thrombocytosis disease | Not yet recruiting | Phase 2 | 2026-05-06 | NCT07468916 | |
| Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL. | B-cell chronic lymphocytic leukemia, Blood Protein Disorders, Chronic Disease, Disease Attributes, Hemic and Lymphatic Diseases, Leukemia, B-Cell, Myeloproliferative Disorders, Neoplasms by Histologic Type, Neoplasms by Site, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Recurrence, Richter transformation, T-cell leukemia, T-cell prolymphocytic leukemia, acute myeloid leukemia, bone marrow disorder, cardiovascular disorder, hematologic disorder, hematopoietic and lymphoid system neoplasm, hemorrhagic disease, immune system disorder, immunoproliferative disorder, leukemia, lymphatic system disorder, lymphoid leukemia, lymphoma, lymphoproliferative syndrome, monoclonal gammopathy, myelodysplastic/myeloproliferative disease, myelodysplastic/myeloproliferative neoplasm, myeloid leukemia, neoplasm, non-Hodgkin lymphoma, plasma cell neoplasm, primary myelofibrosis, prolymphocytic leukemia, vascular disorder, vascular hemostatic disease | Recruiting | Phase 1 | 2026-05-05 | NCT04771572 | |
| Evaluation of Tranexamic Acid in Myelodysplastic Syndromes and Acute Myeloid Leukemia | Cytopenia, Hemic and Lymphatic Diseases, Myeloproliferative Disorders, Neoplasms by Histologic Type, acute myeloid leukemia, blood platelet disease, bone marrow disorder, hematologic disorder, leukemia, myelodysplastic syndrome, myelodysplastic/myeloproliferative disease, myelodysplastic/myeloproliferative neoplasm, myeloid leukemia, neoplasm, thrombocytopenia | Recruiting | Phase 2 | 2026-04-22 | NCT06599762 | |
| Active Myeloid Target Compound Combinations in MDS/MPN Overlap Syndromes Overlap Syndromes (ABNL-MARRO) | myelodysplastic/myeloproliferative neoplasm | Recruiting | Phase 1 / Phase 2 | 2026-04-21 | NCT04061421 | |
| Study Investigating Patient-Reported Outcomes in Lower-risk MDS Patients | Hemic and Lymphatic Diseases, anemia, hematologic disorder, myelodysplastic syndrome, myelodysplastic/myeloproliferative neoplasm | Active, not recruiting | Not stated | 2026-04-14 | NCT05582902 | |
| Tissue, Blood, and Body Fluid Sample Collection From Patients With Hematologic Cancer | B-cell chronic lymphocytic leukemia, B-cell neoplasm, Blood Protein Disorders, Bone Marrow Failure Disorders, Burkitt lymphoma, Carcinogenesis, Cell Transformation, Neoplastic, Chronic Disease, Congenital Abnormalities, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, DNA Virus Infections, Disease Attributes, Epstein-Barr virus infection, Hemic and Lymphatic Diseases, Herpesviridae infectious disease, Hodgkins lymphoma, Immunoglobulin Light-chain Amyloidosis, Infections, Leukemia, B-Cell, Leukemia, Large Granular Lymphocytic, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative, Lymphadenopathy, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Extranodal NK-T-Cell, Mast Cell Activation Disorders, Mastocytosis, Systemic, Myeloproliferative Disorders, Neoplasms by Histologic Type, Neoplasms by Site, Neoplastic Processes, Nutritional and Metabolic Diseases, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma, Sezary syndrome, T-cell leukemia, T-cell non-Hodgkin lymphoma, Tumor Virus Infections, Waldenstrom macroglobulinemia, acquired polycythemia vera, acute biphenotypic leukemia, acute myeloid leukemia, amyloidosis, anaplastic large cell lymphoma, anemia, angioimmunoblastic T-cell lymphoma, aplastic anemia, blast phase chronic myelogenous leukemia, BCR-ABL1 positive, blood coagulation disease, blood platelet disease, bone marrow disorder, bone marrow neoplasm, cardiovascular disorder, chronic eosinophilic leukemia, chronic neutrophilic leukemia, diffuse large B-cell lymphoma, essential thrombocythemia, follicular lymphoma, hairy cell leukemia, hematologic disorder, hematopoietic and lymphoid system neoplasm, hemorrhagic disease, immune system disorder, immunoproliferative disorder, intraocular lymphoma, large-cell immunoblastic lymphoma, leukemia, leukemia, myeloid, accelerated-phase, lymphatic system disorder, lymphoid leukemia, lymphoma, lymphoproliferative syndrome, mantle cell lymphoma, mast cell leukemia, mastocytosis, metabolic disease, monoclonal gammopathy, mycosis fungoides, myelodysplastic syndrome, myelodysplastic/myeloproliferative disease, myelodysplastic/myeloproliferative neoplasm, myeloid leukemia, neoplasm, ocular cancer, plasma cell neoplasm, primary cutaneous T-cell non-Hodgkin lymphoma, primary myelofibrosis, prolymphocytic leukemia, proteostasis deficiencies, thrombocytosis disease, vascular disorder, vascular hemostatic disease, viral infectious disease | Recruiting | Not stated | 2025-10-27 | NCT01137643 |